Medicine from the Genentech Patient Foundation is primarily distributed through our speciality pharmacy partner, Medvantx.
Health care providers can order medicines from the Genentech Patient Foundation in two ways:
Upfront Shipment
Genentech Medicines Eligible for Upfront Shipment
ACTEMRA® (tocilizumab)
Alecensa® (alectinib)
Avastin® (bevacizumab)
COLUMVI™ (glofitamab-gxbm)
Cotellic® (cobimetinib)
ENSPRYNG™ (satralizumab-mwge)
Erivedge® (vismodegib)
Esbriet® (pirfenidone)
Evrysdi® (risdiplam)
GAZYVA® (obinutuzumab)
Gavreto™ (Pralsetinib)
Hemlibra® (emicizumab-kxwh)
Herceptin® (trastuzumab)
Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
ITOVEBI™ (Inavolisib)
KADCYLA® (ado-trastuzumab emtansine)
LUCENTIS® (ranibizumab injection)
LUNSUMIO™ (mosunetuzumab-axgb)
OCREVUS® (ocrelizumab)
OCREVUS ZUNOVO™️ (ocrelizumab and hyaluronidase-ocsq)
PERJETA® (pertuzumab)
PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
PiaSky™ (crovalimab-akkz)
POLIVY™ (polatuzumab vedotin-piiq)
Pulmozyme® (dornase alfa)
Rituxan® (rituximab)
RITUXAN HYCELA® (rituximab/hyaluronidase human)
ROZLYTREK™ (entrectinib)
Susvimo™ (ranibizumab injection)
TECENTRIQ® (atezolizumab)
TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)
Vabysmo® (faricimab-svoa)
Venclexta® (venetoclax)
XOLAIR® (omalizumab) for subcutaneous use
Zelboraf® (vemurafenib)
HCPs can request medicine to be delivered to their patient's home or their office through the Foundation's specialty pharmacy partner via one of the following options:
*Note: If preferred, electronic Prescriptions can be submitted through an e-prescribing software or an electronic medical record that has been certified by Surescripts. Query for Medvantx or AmeriPharm in Sioux Falls, SD 57014. NPI-1073692745 or NCPDP-4351968.
Product Replacement
Genentech Medicines Eligible for Product Replacement
ACTEMRA® (tocilizumab)
ACTIVASE® (alteplase)
Avastin® (bevacizumab)
Cathflo® Activase (alteplase)
COLUMVI™ (glofitamab-gxbm)
GAZYVA® (obinutuzumab)
Hemlibra® (emicizumab-kxwh)
Herceptin® (trastuzumab)
Herceptin HYLECTA™
(trastuzumab and hyaluronidase-oysk)
KADCYLA® (ado-trastuzumab emtansine)
LUCENTIS® (ranibizumab injection)
LUNSUMIO™ (mosunetuzumab-axgb)
OCREVUS® (ocrelizumab)
OCREVUS ZUNOVO™️ (ocrelizumab and hyaluronidase-ocsq)
PERJETA® (pertuzumab)
PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
POLIVY™ (polatuzumab vedotin-piiq)
Rituxan® (rituximab)
RITUXAN HYCELA® (rituximab/hyaluronidase human)
Susvimo™ (ranibizumab injection)
TECENTRIQ® (atezolizumab)
TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)
TNKase® (tenecteplase)
Vabysmo® (faricimab-svoa)
XOLAIR® (omalizumab) for subcutaneous use
HCPs can request replacement medicine when an enrolled patient was treated with medicine from their inventory via one of the following options:
Prescriptions will be distributed through our specialty pharmacy partner or through a product replacement model. For Genentech medicines that are administered by a health care provider, we are asking providers to select one distribution option. If you have questions about shipment options, a Genentech Patient Foundation Specialist can help.
